Transition metal complexes of n,...

Organic compounds -- part of the class 532-570 series – Organic compounds – Heavy metal containing

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S499000, C424S001110, C424S001290, C424S009300, C424S009321, C564S462000

Reexamination Certificate

active

06765104

ABSTRACT:

TECHNICAL FIELD OF THE INVENTION
The present invention relates to transition metal complexes of N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane and related compositions and methods of synthesis and use in vitro and in vivo, such as a therapeutic agent or a delivery/imaging agent.
BACKGROUND OF THE INVENTION
Nucleases that hydrolyze phosphate diester bonds exist in nature. Given that phosphate diester bonds are responsible for the accuracy of the genetic code, there has been interest in developing synthetic metallonucleases that hydrolyze phosphate diester bonds (Bashkin,
Current Biology
7: R286-R288 (1997); Kuusela et al.,
Met. Ions Biol. Syst
. 32: 271-300 (1996); Morrow,
Met. Ions Biol. System
. 33: 561-592 (1996); Sigman et al.,
Chem. Rev
. 93: 2295-2361 (1993)). A variety of inert metal compounds have been evaluated as promoters (or catalysts) of activated phosphate diester hydrolysis (Williams et al.,
J. Am. Chem. Soc
. 120: 8079-8087 (1998); Wahnon et al.,
Chem. Int. Ed. Eng
. 34: 2412-2414 (1995); Hendry et al.,
In Progress in Inorganic Chemistry
38: 201-258, Lippard, ed., John Wiley & Sons, NY (1990); Hendry et al.,
Inorg. Chem
29: 92-97 (1990); Hendry et al.,
J. Am. Chem. Soc
. 111: 2521-2527 (1989); Chin et al.,
J. Am. Chem. Soc
. 111: 186-190 (1989)). Given that most natural nucleases contain one or two labile metal cations in the active site (Williams,
In Comprehensive Biological Catalysts
1: 543-561, Sinnott, ed, Academic Press Ltd., San Diego, Calif. (1998); Cowan,
Chem. Rev
. 98: 1067-1087 (1998); Strater et al.,
Angew. Chem. Int. Ed. Engl
. 35: 2024-2055 (1996)), recent efforts have focused on labile metal complexes like zinc and copper as synthetic nucleases (Yashiro et al.,
Chem. Commun
. 1997: 83-84; Yashiro et al.,
J. Chem. Soc. Chem. Commun
. 1995: 1793-1794; Gobel,
Chem. Int. Ed. Engl
. 33: 1141-1143 (1994); Koike et al.,
J. Am. Chem. Soc
. 113: 8935-8941 (1991); de Rosch et al.,
Inorg. Chem
. 29: 2409-2416 (1990); Morrow et al.,
Inorg. Chem
. 27: 3387-3394 (1988)).
Copper (II) complexes have been explored. One of the first systems evaluated was Cu(2,2′-bipyridine)
2+
-catalyzed hydrolysis of ethyl(p-nitrophenyl)phosphate, and rate enhancements were reported (Morrow et al.,
Inorg. Chem
. 27: 3387-3394 (1988)). Since then, others have explored bipyridine and pyridine derivatives as copper (II) ligands (Kovari et al.,
J. Am. Chem. Soc
. 118: 12704-12709 (1996); Kovari et al.,
J. Chem. Soc. Chem. Commun
. 1995: 1205-1206; Young et al.,
J. Am. Chem. Soc
. 117: 9441-9447 (1995)). A variety of activated phosphate diesters and activated transesterification substrates, like bis(2,4-dinitrophenyl)phosphate (Young et al. (1995), supra), bis(p-nitrophenyl)phosphate (Kovari et al. (1996), supra; Kovari et al. (1995), supra), and 2-hydroxypropyl-p-nitrophenyl phosphate (hpnp; Wall et al.,
Angew. Chem. Int. Ed Engl
. 32: 1633-1635 (1993); Wahnon et al.,
J. Chem. Soc. Chem. Commun
. 1994: 1441-1442) have been used to determine the activity of the metal complexes.
Detailed kinetics and mechanistic studies of labile metal-promoted hydrolysis have been reported for the copper (II) triazacyclononane system (Deal et al.,
Inorg. Chem
. 35: 2792-2798 (1996); see, also, Hegg et al.,
J. Am. Chem. Soc
. 117: 7015-7016 (1995); Hegg et al.,
Inorg. Chem
. 35: 7474-7481 (1996); and Hegg et al.,
Inorg. Chem
. 36: 1715-1718 (1997)). Deal and co-workers measured a half-order metal complex dependence attributed to the formation of an inactive di-hydroxide bridged copper(II) dimer in equilibrium with the active mononuclear species (Deal et al. (1996), supra; Fromm,
Initial Rate Enzyme Kinetics
, Springer-Verlag, NY (1975), pp. 209-213). Studies by others with additional copper (II) complexes also have noted the half-order dependence (Wahnon et al. (1994), supra).
It has been suggested that a dinuclear copper complex which retains open coordination sites on the metal face may better promote phosphate diester hydrolysis (Deal et al.,
J. Am. Chem. Soc
. 118: 1713-1718 (1996)). Wahnon and co-workers (Wahnon et al. (1994), supra) noted that the copper complex of bis(2-benzimidazolylmethyl)amine had an increase in the transesterification rate of hpnp with high metal complex concentrations, which was ascribed to an active dimer. The ligand is bulky, implying that steric constraints placed on the metal complex by the ligand may inhibit dimer formation.
Recently, Itoh and co-workers (Itoh et al.,
Chem. Commun
. 1997: 677-678) reported that the hydrolysis of ethyl(2,4-dinitrophenyl)phosphate by the copper(II) complex of cis,cis-1,3,5-triaminocyclohexane (tach) was significantly greater than that for several other tramino ligands. Until recently, the availability of tach and derivatives thereof was limited by the synthetic procedure.
In view of the above, it is an object of the present invention to provide new synthetic metallonucleases, in particular transition metal complexes of novel derivatives of tach. The novel derivatives of tach enable the formation of complexes with many transition metals and the resultant metallonucleases cleave activated phosphate diesters at an unprecedented rate and demonstrate concentration-dependent cytotoxicity. It is a related object of the present invention to provide a method of synthesizing tach. Such a synthesis route does not suffer from the disadvantages of complexity and low yield associated with currently available methods of synthesis, being less complicated and providing tach in high yield. It is another object of the present invention to provide conjugates of the transition metal complexes of novel derivatives of tach. It is yet another object of the present invention to provide methods of using such complexes and conjugates thereof. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the detailed description provided herein.
BRIEF SUMMARY OF THE INVENTION
The present invention provides a transition metal complex of N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane. Preferably, the transition metal is copper, in particular copper II (Cu (II)). The trialkyl preferably comprises C
1
-C
6
alkyl groups, which may be the same or different. Preferably, the trialkyl is trimethyl or triethyl, with trimethyl being especially preferred. The transition metal can be radioactive, such as a positron emitter, e.g., Cu
64
, or a &bgr;-emitter, e.g, Cu
67
.
The transition metal complex of N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane can be conjugated to a targeting agent. Preferably, the targeting agent is an immunological agent, a protein, a polypeptide, a peptide, a nucleic acid or a steroid.
Also provided by the present invention is a composition comprising a transition metal complex of N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane, or a conjugate thereof, and a carrier therefor.
In addition to the above, the present invention provides a method of synthesizing N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane. The method comprises derivatizing 1,3,5-cis,cis-triaminocyclohexane to a tris-sulfonamide, removing the sulfonamide proton with a base to generate a tris-anion, quenching the tris-anion with an alkylating agent, and cleaving the sulfonamide group with an acid to generate N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane as a protonated salt. The method can further comprise adding an equimolar amount of CuX
2
in water to the N,N′,N″-trialkyl-cis,cis-1,3,5-triaminocyclohexane, neutralizing the resulting solution with base solution (to form a deep-blue solution), and removing the hydroxides that form by filtration to yield a solution of the Cu (II) complex.
Further provided by the present invention is a method of cleaving a biological molecule. The method comprises contacting the biological molecule with an above-described complex, which cleaves the biological molecule. Preferably, the biological molecule is in vivo and the cleavage of the bi

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Transition metal complexes of n,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Transition metal complexes of n,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transition metal complexes of n,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3237090

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.